English
Français
Deutsch
Italiano
Русский
Español
हिन्दी
简体中文
한국어
日本語
Telix Pharmaceuticals Limited (NASDAQ:TLX) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 12:00 PM EDT
Company Participants
Christian Behrenbruch – Co-Founder, MD, Group CEO & Executive Director
Conference Call Participants
Robert Burns – H.C. Wainwright & Co, LLC, Research Division
Presentation
Robert Burns
Managing Director & Senior Healthcare Analyst
Welcome to our next fireside chat. I’m Robert Burns, Managing Director and Senior Biotech Analyst, H.C. Wainwright. And I am joined today by Christian Behrenbruch, the CEO of Telix Pharmaceuticals. Christian, thank you for joining us today.
Christian Behrenbruch
Co-Founder, MD, Group CEO & Executive Director
Yes. Thanks for the opportunity.
Question-and-Answer Session
Robert Burns
H.C. Wainwright & Co, LLC, Research Division
So one of the things that I first wanted to start off with was obviously, Telix has experienced rapid growth and transformation over the years. So can you share some of the key factors that have contributed to the success?
Christian Behrenbruch
Co-Founder, MD, Group CEO & Executive Director
Well, I think the company is just really passionate about radiopharmaceuticals. I think one of the unique aspects about the company is we don’t really believe in isotope platforms, right? We think that when you develop a radiopharmaceutical, you should look at the clinical application that you want to solve.
You should think about what pharmacophore achieves your biological objectives best. And then you should choose the right isotope for the job. And so one of the things that I think is really special about the company, and it’s reflected in the infrastructure that we’ve built over the last — almost — company is almost 10 years old, 8 years as a public company is that agnosticism.
We want a — we’re very — we’re a pure-play radio pharma company. We believe that precision medicine is really important. That’s kind of something that isn’t
Read the full article here
